CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 10-Q Report Quarterly Report
- 8-K Event Results of operations · Other events
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 8-K Event Results of operations · Other events
- 4 Open-market sale CFO and Treasurer sold 1,428 shares at $19.48 ($27,817)
- 4 Open-market sale COO and Secretary sold 1,427 shares at $19.49 ($27,812)
- 4 Open-market sale Chief Medical Officer sold 1,428 shares at $19.48 ($27,817)
- 4 Open-market sale President and CEO sold 4,807 shares at $19.48 ($93,640)
- 4/A Option exercise CFO and Treasurer acquired 4,250 shares (option exercise)
- 4/A Option exercise COO and Secretary acquired 4,250 shares (option exercise)
- 4/A Option exercise Chief Medical Officer acquired 4,250 shares (option exercise)
- 4/A Option exercise President and CEO acquired 14,315 shares (option exercise)
- 4 Open-market sale 10% owner sold 3,894,764 shares at $20.25 ($78,868,971)
- S-8 Other Securities Offered to Employees in Benefit Plans
Page 29 of 40 · 789 filings